论文部分内容阅读
目的探讨分析纤溶酶联合依达拉奉治疗脑梗死患者的临床疗效以及不良反应情况。方法选取从2010年7月至2012年10月在本院进行治疗的80例脑梗死的患者作为研究对象,随机平均分为对照组和观察组。对照组应用常规治疗方法进行治疗;观察组在对照组的基础上(除外阿司匹林肠溶片)应用纤溶酶联合依达拉奉进行治疗。观察两组患者治疗后的临床总有效率、神经功能缺损评分以及不良反应等情况。结果治疗后观察组和对照组的临床总有效率、不良反应发生率分别为95%、2.5%和75%、15%,其差异均有统计学意义(P<0.05)。治疗后两组的神经功能缺损评分均降低,观察组较对照组降低的更加显著,比较两组差异具有统计学意义(P<0.05)。结论纤溶酶联合依达拉奉治疗脑梗死患者的临床疗效显著,不良反应少,安全性高,值得临床推广应用。
Objective To investigate the clinical efficacy and side effects of plasmin combined with edaravone in patients with cerebral infarction. Methods Eighty patients with cerebral infarction who were treated in our hospital from July 2010 to October 2012 were randomly divided into control group and observation group. The patients in the control group were treated by conventional treatment. The observation group was treated with plasmin combined with edaravone on the basis of the control group (except for aspirin enteric-coated tablets). The total effective rate of treatment, neurological deficit score and adverse reactions of the two groups were observed after treatment. Results After treatment, the clinical total effective rate and adverse reaction rate in observation group and control group were 95%, 2.5%, 75% and 15%, respectively. The difference was statistically significant (P <0.05). After treatment, the scores of neurological deficit in both groups were decreased, and the observation group was more significant than the control group. The difference between the two groups was statistically significant (P <0.05). Conclusions The combination of plasmin and edaravone in the treatment of patients with cerebral infarction has significant clinical efficacy, less adverse reactions, high safety and worthy of clinical application.